Abg Abd Wahab DY et al (2019) Review on cross talk between neurotransmitters and neuroinflammation in striatum and cerebellum in the mediation of motor behaviour. BioMed Res In. https://doi.org/10.1155/2019/1767203

Article  Google Scholar 

Alam M, Schwabe K, Krauss JK (2011) The pedunculopontine nucleus area: critical evaluation of interspecies differences relevant for its use as a target for deep brain stimulation. Brain 134(1):11–23

Article  PubMed  Google Scholar 

Armstrong P et al. (2024) ‘Protective effect of PDE4B subtype-specific inhibition in an App knock-in mouse model for Alzheimer’s disease’, Neuropsychopharmacology, pp. 1–10

Atya SM (2024) cAMP/PKA-CREB-BDNF signaling cascade and phosphodiesterase 4 inhibition: a possible neuroprotective approach in Alzheimer’s disease. Records Pharmaceut Biomed Sci 8(1):158–168

Article  Google Scholar 

Bergantin LB (2022) A timeline of Ca2+/cAMP signalling: from basic research to potential therapeutics for dementia. Curr Alzheimer Res 19(3):179–187

Article  PubMed  Google Scholar 

Blokland A et al (2019) Acute treatment with the PDE4 inhibitor roflumilast improves verbal word memory in healthy old individuals: a double-blind placebo-controlled study. Neurobiol Aging 77:37–43

Article  PubMed  Google Scholar 

Breckler M et al (2011) Rap-linked cAMP signaling Epac proteins: compartmentation, functioning and disease implications. Cell Signal 23(8):1257–1266

Article  PubMed  Google Scholar 

Carlyle BC et al (2014) cAMP-PKA phosphorylation of tau confers risk for degeneration in aging association cortex. Proc Natl Acad Sci 111(13):5036–5041

Article  PubMed  PubMed Central  Google Scholar 

Chen C, Bazan NG (2005) Lipid signaling: Sleep, synaptic plasticity, and neuroprotection. Prostaglandins Lipid Mediat. https://doi.org/10.1016/j.prostaglandins.2005.07.001

Article  Google Scholar 

Cheng Y-F et al (2010) Inhibition of phosphodiesterase-4 reverses memory deficits produced by Aβ25–35 or Aβ1–40 peptide in rats. Psychopharmacology 212:181–191

Article  PubMed  Google Scholar 

Choi CH et al (2015) PDE-4 inhibition rescues aberrant synaptic plasticity in Drosophila and mouse models of fragile X syndrome. J Neurosci 35(1):396–408

Article  PubMed  PubMed Central  Google Scholar 

Christiansen SH et al (2011) Combined anti-inflammatory effects of β2-adrenergic agonists and PDE4 inhibitors on astrocytes by upregulation of intracellular cAMP. Neurochem Int 59(6):837–846

Article  PubMed  Google Scholar 

Cong Y-F et al (2023) Rolipram ameliorates memory deficits and depression-like behavior in APP/PS1/tau triple transgenic mice: involvement of neuroinflammation and apoptosis via cAMP signaling. Int J Neuropsychopharmacol 26(9):585–598

Article  PubMed  PubMed Central  Google Scholar 

Crocetti L et al (2022) An overview of PDE4 inhibitors in clinical trials: 2010 to early 2022. Molecules 27(15):4964

Article  PubMed  PubMed Central  Google Scholar 

Dastidar SG, Rajagopal D, Ray A (2007) Therapeutic benefit of PDE4 inhibitors in inflammatory diseases. Curr Opin Investig Drugs 8(5):364

PubMed  Google Scholar 

Dong X-L et al (2021) The protective effect of the PDE-4 inhibitor rolipram on intracerebral haemorrhage is associated with the cAMP/AMPK/SIRT1 pathway. Sci Rep 11(1):19737

Article  PubMed  PubMed Central  Google Scholar 

Fan T et al (2024) PDE4 inhibitors: potential protective effects in inflammation and vascular diseases. Front Pharmacol 15:1407871

Article  PubMed  PubMed Central  Google Scholar 

Feng H et al (2019) Roflumilast ameliorates cognitive impairment in APP/PS1 mice via cAMP/CREB/BDNF signaling and anti-neuroinflammatory effects. Metab Brain Dis 34:583–591

Article  PubMed  Google Scholar 

Fertig BA, Baillie GS (2018) PDE4-mediated cAMP signalling. J Cardiovas Dev Dis 5(1):8

Google Scholar 

Fusco FR, Paldino E (2017) Promising Candidates for Drug Repurposing in Huntington’s Disease, in Drug Repositioning. CRC Press, pp. 221–240

Gilleen J et al (2021) An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients. Psychopharmacology 238:1279–1289

Article  PubMed  Google Scholar 

Gomaa AA et al (2023) Intermittent treatment with Apremilast, a phosphodiesterase-4 inhibitor, ameliorates Alzheimer’s-like pathology and symptoms through multiple targeting actions in aged T2D rats. Int Immunopharmacol 117:109927

Article  PubMed  Google Scholar 

Gonçalves-Ribeiro J et al (2019) Glutamate transporters in hippocampal LTD/LTP: not just prevention of excitotoxicity. Front Cell Neurosci 13:357

Article  PubMed  PubMed Central  Google Scholar 

Gopalakrishna R et al (2022) cAMP-induced decrease in cell-surface laminin receptor and cellular prion protein attenuates amyloid-β uptake and amyloid-β-induced neuronal cell death. FEBS Lett 596(22):2914–2927

Article  PubMed  PubMed Central  Google Scholar 

Grandoch M, Roscioni SS, Schmidt M (2010) The role of Epac proteins, novel cAMP mediators, in the regulation of immune, lung and neuronal function. Br J Pharmacol 159(2):265–284

Article  PubMed  Google Scholar 

Hansen RT, Zhang HT (2017) ‘The past, present, and future of phosphodiesterase-4 modulation for age-induced memory loss’, Phosphodiesterases: CNS Funct Dis pp. 169–199

Hansen T, Zhang R (2015) Phosphodiesterase-4 modulation as a potential therapeutic for cognitive loss in pathological and non-pathological aging: possibilities and pitfalls. Curr Pharmaceut Design 21(3):291–302

Google Scholar 

Harada A, Suzuki K, Kimura H (2017) TAK-063, a novel phosphodiesterase 10A inhibitor, protects from striatal neurodegeneration and ameliorates behavioral deficits in the R6/2 mouse model of Huntington’s disease. J Pharmacol Exp Ther 360(1):75–83

Article  PubMed  Google Scholar 

Hawley SA et al (2012) The ancient drug salicylate directly activates AMP-activated protein kinase. Science 336(6083):918–922

Article  PubMed  PubMed Central  Google Scholar 

Jin S-X et al (2022) Aβ oligomers from human brain impair mossy fiber LTP in CA3 of hippocampus, but activating cAMP-PKA and cGMP-PKG prevents this. Neurobiol Dis 172:105816

Article  PubMed  PubMed Central  Google Scholar 

Kaundal M et al (2018) Betulinic acid, a natural PDE inhibitor restores hippocampal cAMP/cGMP and BDNF, improve cerebral blood flow and recover memory deficits in permanent BCCAO induced vascular dementia in rats. Eur J Pharmacol 832:56–66

Article  PubMed  Google Scholar 

Koh W et al (2022) Astrocytes render memory flexible by releasing D-serine and regulating NMDA receptor tone in the hippocampus. Biol Psychiat 91(8):740–752

Article  PubMed  Google Scholar 

Kumari S, Deshmukh R (2021) β-lactam antibiotics to tame down molecular pathways of Alzheimer’s disease. Eur J Pharmacol 895:173877

Article  PubMed  Google Scholar 

Kumari S, Agrawal M, Deshmukh RR (2022) Fingolimod (FTY720) offers neuroprotection against AlCl3 induced experimental dementia in rats. Alzheimer’s Dementia 18:e067689

Article  Google Scholar 

Leslie SN et al (2020) Phosphodiesterase PDE4D is decreased in frontal cortex of aged rats and positively correlated with working memory performance and inversely correlated with PKA phosphorylation of tau. Front Aging Neurosci 12:576723

Article  PubMed  PubMed Central  Google Scholar 

Li Q-Q et al (2015) Hippocampal cAMP/PKA/CREB is required for neuroprotective effect of acupuncture. Physiol Behav 139:482–490

Article  PubMed  Google Scholar 

Lin C-H, Chang S-H, Fang J-Y (2016) Recent advances using phosphodiesterase 4 (PDE4) inhibitors to treat inflammatory disorders: animal and clinical studies. Curr Drug Therapy 11(1):21–40

Article  Google Scholar 

Liu Z et al (2022) Phosphodiesterase-4 inhibitors: a review of current developments (2013–2021). Expert Opin Ther Pat 32(3):261–278

Article  PubMed  Google Scholar 

Lugnier C (2022) The complexity and multiplicity of the specific cAMP phosphodiesterase family: PDE4, open new adapted therapeutic approaches. Int J Mol Sci 23(18):10616

Article  PubMed  PubMed Central